WOBURN, Mass., June 09, 2021 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today reported that top-line results from a randomized controlled trial of Quell in patients with fibromyalgia will be presented at two upcoming pain medicine conferences.

By A Silva